![](/img/cover-not-exists.png)
Reply to the letter by Chatterjee et al “Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial”
Jeffery S. Berger, Deepak L. BhattVolume:
163
Year:
2012
Language:
english
Pages:
1
DOI:
10.1016/j.ahj.2011.10.005
File:
PDF, 45 KB
english, 2012